Vincenzo Silani is Professor of Neurology, Director of the Department of Neurology-Stroke Unit and Laboratory of Neuroscience of the University of Milan Medical School at the IRCCS Istituto Auxologico Italiano in Milano. He is also the Scientific Director of the “Dino Ferrari” Center for Neuromuscular and Neurodegenerative Disease. In 1979-81 he was a post-doctoral fellow in the Department of Neurology-Baylor College of Medicine in Houston and a Visiting Professor in Neurology in 1999. He was co-chairman (2002-2005) and chairman (2005-2007) of the European ALS Consortium (EALSC); co-director of the European Academy of Neurology Subspeciality Panel ALS and Frontotemporal Dementia (2003-2019). He is author of more than 300 scientific publications in major international journals. He is internationally recognised as a leading scientist in ALS/FTD and he established an ALS/FTD/PD Centre in Milan with a large database of familiar and sporadic cases. He founded the SLAGEN Consortium in Italy (2010). He largely contributed in defining the expression of different new genes in both SALS and FALS, investigating the functional role of TDP43, FUS/TLS, and C9ORF72 using iSCPs. He has been P.I. of many clinical trials and recipient of several grants.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.